Evidence map›Paper›PMID 40861257›Full record

ArticleOnco2025

Mirtrons in Human Cancers.

Yi-Ling Chen, Nicholas Pascuzzi, Alejandro Ruiz, Kuan-Hui Ethan Chen

Abstract read
In one paragraph

Article in Onco, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi-Ling ChenDepartment of Electronic Engineering, National Kaohsiung University of Science and Technology, Kaohsiung 80778, Taiwan.ORCID 0009-0007-4017-0740
Nicholas PascuzziDepartment of Biological Sciences; Texas Tech University, Lubbock, TX 79409, USA.ORCID 0009-0001-5671-3275
Alejandro RuizDepartment of Biological Sciences; Texas Tech University, Lubbock, TX 79409, USA.
Kuan-Hui Ethan ChenDepartment of Biological Sciences; Texas Tech University, Lubbock, TX 79409, USA.

Funding

Dissecting the role of mirtrons in human cancersR16GM153648 · NIGMS · TEXAS TECH UNIVERSITY · PI Ethan Chen · 2024 to 2026
$465k
NIGMS NIH HHS R16 GM153648
6 · The paper itself

Abstract

Mirtrons represent a new subclass of microRNAs (miRNAs) that are processed through non-canonical biogenesis pathways. Unlike canonical miRNAs, which require Drosha-mediated cleavage, mirtrons are generated via the splicing of short intronic sequences, bypassing Drosha entirely. While mirtrons are found across a variety of organisms, their conservation between species is relatively low. This evolutionary divergence has resulted in mirtrons acquiring species-specific regulatory functions. In humans, mirtrons remain an understudied group of regulatory RNAs. However, emerging evidence highlights their critical roles in cancer biology. These small RNAs influence a range of oncogenic processes, including tumor initiation, progression, metastasis, and resistance to therapy. By directly regulating the expression of oncogenes and tumor suppressor genes, mirtrons serve as key molecular mediators within cellular signaling pathways. What sets mirtrons apart from canonical miRNAs is their unique mode of biogenesis and structural attributes, which reveal alternative regulatory mechanisms that could be exploited in cancer biology. Recent advances in understanding their functions suggest that mirtrons hold significant potential as biomarkers for cancer diagnosis and prognosis. Additionally, their role as modulators of cancer pathways positions them as promising therapeutic targets in precision oncology. This review delves into the growing body of research on mirtrons, focusing on their biogenesis, biological roles, and implications in cancer. By emphasizing their distinct features and clinical relevance, it aims to provide a comprehensive perspective on the potential applications of mirtrons in advancing cancer diagnostics and therapeutics.

Indexed as

drosha independentmirtronsprecision targetingspecies specific regulation

Identifiers

PMID40861257
PMCPMC12377645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.